Key Points
- Hamid Khoja bought 30,000 shares of FibroBiologics at an average of $0.38 on March 4 (purchase value $11,400), boosting his holding 96% to 61,250 shares valued at about $23,275.
- Stock snapshot: FBLG traded at $0.43 midday with a market cap of $29.09M, a one‑year range of $0.22–$1.53, negative PE (-1.02), and 50/200‑day moving averages of $0.30/$0.38.
- Analysts & institutional activity: Q4 EPS beat estimates (-$0.03 vs -$0.09), several analysts cut price targets (e.g., to $7 and $4) leaving a consensus "Hold" with a $5.50 target, while funds like Renaissance, Jane Street and Geode recently added or increased positions.
FibroBiologics Inc. (NASDAQ:FBLG - Get Free Report) insider Hamid Khoja purchased 30,000 shares of the company's stock in a transaction that occurred on Wednesday, March 4th. The shares were purchased at an average cost of $0.38 per share, with a total value of $11,400.00. Following the completion of the purchase, the insider owned 61,250 shares of the company's stock, valued at $23,275. The trade was a 96.00% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.
FibroBiologics Price Performance
Shares of NASDAQ FBLG traded up $0.01 during midday trading on Friday, reaching $0.43. 484,558 shares of the stock traded hands, compared to its average volume of 1,392,710. The company's 50 day moving average is $0.30 and its 200 day moving average is $0.38. FibroBiologics Inc. has a one year low of $0.22 and a one year high of $1.53. The stock has a market capitalization of $29.09 million, a PE ratio of -1.02 and a beta of -0.69.
FibroBiologics (NASDAQ:FBLG - Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.06. As a group, equities analysts forecast that FibroBiologics Inc. will post -0.53 EPS for the current year.
Hedge Funds Weigh In On FibroBiologics
Several large investors have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new position in shares of FibroBiologics during the 4th quarter worth about $34,000. Renaissance Technologies LLC increased its stake in shares of FibroBiologics by 287.3% during the 4th quarter. Renaissance Technologies LLC now owns 231,600 shares of the company's stock worth $52,000 after purchasing an additional 171,800 shares in the last quarter. Geode Capital Management LLC lifted its stake in FibroBiologics by 20.7% in the 4th quarter. Geode Capital Management LLC now owns 348,761 shares of the company's stock valued at $78,000 after buying an additional 59,813 shares in the last quarter. AMG National Trust Bank acquired a new stake in FibroBiologics during the 4th quarter valued at $31,000. Finally, Yorkville Advisors Global LP purchased a new position in FibroBiologics during the third quarter worth $278,000.
Analyst Ratings Changes
Several equities analysts recently issued reports on FBLG shares. D. Boral Capital cut their price target on shares of FibroBiologics from $15.00 to $7.00 and set a "buy" rating for the company in a report on Wednesday, February 25th. HC Wainwright decreased their price target on FibroBiologics to $4.00 and set a "buy" rating on the stock in a research report on Thursday, February 26th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of FibroBiologics in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, FibroBiologics currently has a consensus rating of "Hold" and a consensus price target of $5.50.
Check Out Our Latest Report on FibroBiologics
About FibroBiologics
(
Get Free Report)
FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
